Cargando…
Intravitreal Bevacizumab as a Primary Treatment for Idiopathic Choroidal Neovascularization
PURPOSE: To report long-term outcomes of the use of intravitreal bevacizumab in subjects with idiopathic choroidal neovascularization (ICNV). MATERIALS AND METHODS: Six consecutive subjects with ICNV were included in this prospective study. All subjects received 1.25 mg intravitreal bevacizumab at d...
Autores principales: | Cheema, Rizwan A., Mushtaq, Javed, Cheema, Maheera A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162734/ https://www.ncbi.nlm.nih.gov/pubmed/21887077 http://dx.doi.org/10.4103/0974-9233.84051 |
Ejemplares similares
-
Choroidal osteoma with choroidal neovascular membrane: Successful treatment with intravitreal bevacizumab
por: Pandey, Neeraj, et al.
Publicado: (2010) -
Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
por: Najafabadi, Farhad Fazel, et al.
Publicado: (2015) -
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018) -
Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta
por: Rishi, Pukhraj, et al.
Publicado: (2012) -
Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
por: Palejwala, Neal V, et al.
Publicado: (2014)